Respiratory Disease Testing Market, By Test Type (Imaging Test, Spirometry, Peak Flow Test, Blood Gas Test, Lung Volume Test, Others), By End User (Hospitals, Physician Offices, Clinical Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jul 2023

Code : CMI4030

Pages :178

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Global Respiratory Disease Testing Market: Key Developments

In February 2022, Carestream Health is Medical equipment supplier in Mumbai, Maharashtra, India, announced the launch of The DRX Compass, an accurate, convenient & configurable digital radiology solution designed to provide radiologists with a whole new level of efficiency. Additionally, DRX Compass offers the versatility to build the desired configuration from a wide range of selections in detectors, tubes, generators, tables, collimators, giving Radiology facilities full control over how they can use this future-proof digital radiology technology.

In July 2022, FUJIFILM Healthcare Corporatio, an unrivaled selection of digital X-ray (digital radiography) systems, launched the FDR Cross, a hybrid c-arm and portable x-ray solution built for hospitals and ambulatory surgery centers (ASC), Two-in-One Fluoroscopy and Digital Radiography System. The ability to offset the x-ray tube from the built-in detector accommodates wireless x-ray imaging akin to that of a standard portable x-ray, including table-top, cross-table, even wheelchair, and standing chest exams.

In December 2022, Canon Inc., specializing in optical, imaging, and industrial products, such as lenses, cameras, medical equipment, scanners, printers, and semiconductor manufacturing equipment, announced the launch in July, in markets outside of Japan1, of the CXDI-Elite series of wireless digital radiography (DR2) devices, including the CXDI-720C Wireless sensor unit.

In July 2021, Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) in a single, one hour, 1,200 mg infusion. The U.S. Food and Drug Administration approved KIMYRSA on March 12, 2021, for the treatment of adult patients with ABSSSI caused by susceptible isolates of designated gram-positive microorganisms.

On June 06, 2023, Spexis AG , a clinical-stage biopharmaceutical company focused on rare diseases and oncology, announced the publication of preclinical results from the company’s novel class of macrocyclic, peptidomimetic antibiotics developed, in collaboration with the University of Zurich, demonstrating potent in vitro and in vivo antimicrobial activity against multidrug resistant (MDR) and extensively drug resistant (XDR) Enterobacteriaceae.